Table 2.

Individual descriptions of the 27 female pations.

Patient number	Age at start (years)	Target organs	Sirolimus exposure (months)	Daily dose (mg) of sirolimus	Combining DMARDs	Cause of cessation	Number of DMARDs ahead of sirolimus	SDI at start	SDI at last follow-up on sirolimus
1	58	Musculoskeletal, leukocytopenia	117	2	HQ	Treatment ongoing	2	1	1
2	65	Musculoskeletal, discoid lupus	10	3	None	Rash, swelling of legs	3	6	6
3	43	Musculoskeletal	18	1	HQ, MMF	Decreasing effect	6	3	3
4	53	Musculoskeletal	96	1	None	Treatment ongoing	4	0	1
5	62	Musculoskeletal	35	2	HQ, MTX	Itching, headache	5	1	3
6∗†	51	Musculoskeletal, leukocytopenia	3	1	None	Infection, lack of efficacy	6	2	2
7	59	Musculoskeletal, malar rash	13	1	HQ	Increased liver enzymes	3	0	1
8	37	Musculoskeletal, alopecia, pleuritis	4	2	None	Nausea	5	1	1
9	27	Musculoskeletal	129	1	HQ	Treatment ongoing	4	0	2
10†	56	Musculoskeletal	31	2	None	Malignancy	3	1	1
11	35	Musculoskeletal	7	1	None	Itching, fatigue	2	1	1
12	61	Musculoskeletal	63	2	HQ	Treatment ongoing	2	1	2
13	44	Musculoskeletal	140	3	HQ, MMF	Treatment ongoing	4	1	1
14	52	Musculoskeletal	111	2	None	Treatment ongoing	3	1	2
15†	50	Musculoskeletal, malar rash	127	2	None	Infections	5	2	7
16∗	32	Musculoskeletal	2	1	HQ	Nausea	3	0	0
17	38	Musculoskeletal, photosensitivity	4	1	HQ	Lack of efficacy	4	0	0
18∗	48	Musculoskeletal	3	1	HQ	Nausea	2	0	0
19	20	Musculoskeletal	70	1	HQ	Reached remission	4	0	0
20	50	Musculoskeletal	104	1	HQ	Angioedema	4	0	1
21	48	Musculoskeletal	7	1	HQ, MMF	Nausea	3	1	1
22	21	Lupus profundus	27	1	HQ	Diarrhea	6	1	1
23∗	38	Musculoskeletal, malar rash	3	1	None	Nausea	2	0	0
24	34	Musculoskeletal, photosensitivity	135	1	HQ	Treatment ongoing	2	0	0
25∗†	44	Musculoskeletal	3	1	None	Infections	2	0	0
26∗†	29	Musculoskeletal, alopecia	2	2	MTX	Nausea	5	3	3
27	40	Musculoskeletal, oral/genital ulcers, acute cutaneous lupus	10	2	HQ	Lack of efficacy	5	0	0

^∗Early cessation (≤3 months). ^†Deceased at the end of study period. HQ, hydroxychloroquine; MMF, mycophenolate mofetil; MTX, methotrexate.